The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery

Vural, Ece Turan; Torun-Acar, Banu; Kıvanç, Sertaç Argun; Acar, Suphi

doi:10.2147/opth.s19469

Cited by 33 publications

(27 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bahar et al [18] showed that the use of fibrin glue was associated with a significantly shorter operative time and greater patient acceptance compared with using sutures. We observed [19]. Tok et al used cyclosporine following primary excision in primary pterygium cases, and observed the recurrence of 12.9% [13], Aydin et al who used topical cyclosporine with conjunctival limbal autograft observed a recurrence of 3.4% [20] and Ozulken K et al observed a recurrence of 7.7% with cyclosporine [21].…”

Section: Discussionmentioning

confidence: 62%

Role of Pre And Postoperative Topical Cyclosporine (0.05%) on Recurrence in Recurrent And Vascularised Pterygium

Dhar¹,

Kapoor²,

Parihar³

2017

IOSR JDMS

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 62%

Role of Pre And Postoperative Topical Cyclosporine (0.05%) on Recurrence in Recurrent And Vascularised Pterygium

Dhar¹,

Kapoor²,

Parihar³

2017

IOSR JDMS

View full text Add to dashboard Cite

show abstract

“…The authors postulated that artificial tears could help decrease inflammation in the early postoperative period by improving tear film function. In addition, postoperative application of cyclosporine is associated with lower rates of recurrences and complications following pterygium excision [27,28]. Of note, preoperative dry eye was found to be the most important prognostic parameter for conjunctival limbal graft survival in a series of 31 patients with total limbal stem-cell deficiency [29].…”

Section: Discussionmentioning

confidence: 99%

Dry-Eye Disease in Recurrent Pterygium

Tan

Vollmer‐Conna

Tat³

et al. 2018

Ophthalmic Res

View full text Add to dashboard Cite

Purpose: The aim of this paper was to investigate the degree of inflammation and dry-eye disease (DED) in recurrent pterygium. Methods: Fifty-five patients with a history of pterygium excision were divided into 3 groups – Group 1: no recurrence after the first excision; Group 2: recurrence after the first excision; Group 3: no recurrence after the second excision. Dry-eye symptoms and tear production were elicited for each patient. Results: A high prevalence of DED was observed in patients with primary and recurrent pterygium based on self-reported dry-eye symptoms (63.6%) and an abnormal Schirmer test result (78.1%). There was a statistically significant difference (p = 0.025) in the Schirmer test values between patients with (5.6 mm) and without (11.4 mm) recurrence after surgery for primary pterygium. Patients who were cured after a second excision had an improved Schirmer test value (9.5 mm), although this was not significant. Conclusion: Pterygium recurrence is associated with a greater severity of dry eye, possibly by perpetuating ocular surface inflammation in the postoperative period.

show abstract

“…CsA, an anti-inflammatory agent, has been administered topically to treat a variety of inflammatory disorders of the ocular surface [60]. Postoperative application of topical 0.05% CsA can provide effective prevention of recurrence after primary pterygium surgery [64, 65, 95]. To the best of our knowledge, no previous studies have examined the relationship between MMP-3 and MMP-13 expression by pterygium explants and cultured pterygium-derived fibroblasts, and treatment using bevacizumab and/or CsA.…”

Section: Discussionmentioning

confidence: 99%

Inhibition of Pterygium Fibroblast Migration and Outgrowth by Bevacizumab and Cyclosporine A Involves Down-Regulation of Matrix Metalloproteinases-3 and -13

et al. 2017

View full text Add to dashboard Cite

We examined the connection between matrix metalloproteinase (MMP) expression/activity and pterygium fibroblast migration, and how these were affected by bevacizumab and/or cyclosporine A (CsA). Fibroblasts were obtained from 20 pterygia and 6 normal conjunctival specimens. Expression levels of MMP-3 and MMP-13 were examined after bevacizumab administration. Immunofluorescence staining was used to examine expression of both MMPs in fibroblasts migrating out from explanted pterygium tissues. Rates of cell migration from explant-cultured pterygia tissues and scratch-wounded confluent pterygium fibroblasts were examined in the presence of MMP-3 or MMP-13 inhibitors, as well as bevacizumab and/or CsA. A scratch wound healing migration assay was performed to determine the effects of bevacizumab and/or CsA. Protein expression of both MMPs in pterygium tissues and in cells migrating from organ-cultured pterygium tissues was greater than that observed in normal cells. Inhibition of the activities of both MMPs decreased their expression levels; these were also significantly reduced in bevacizumab-injected pterygium tissues. Bevacizumab significantly reduced the expression of both MMPs and cell migration. Pretreatment with CsA prior to bevacizumab exposure markedly inhibited cell migration and the expression of both MMPs. CsA enhanced the inhibitory effects of bevacizumab on pterygium fibroblast migration in vitro, possibly by inhibiting expression of both MMPs. These findings suggest that combined CsA and bevacizumab treatment may provide a potential therapeutic strategy for reducing the rate of pterygium recurrence.

show abstract

The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery

Cited by 33 publications

References 26 publications

Role of Pre And Postoperative Topical Cyclosporine (0.05%) on Recurrence in Recurrent And Vascularised Pterygium

Role of Pre And Postoperative Topical Cyclosporine (0.05%) on Recurrence in Recurrent And Vascularised Pterygium

Dry-Eye Disease in Recurrent Pterygium

Inhibition of Pterygium Fibroblast Migration and Outgrowth by Bevacizumab and Cyclosporine A Involves Down-Regulation of Matrix Metalloproteinases-3 and -13

Contact Info

Product

Resources

About